Join the Acute Coronary Syndrome group to help and get support from people like you.
Acute Coronary Syndrome News (Page 2)
Do You Really Need to Fast Before a Common Cardiac Test?
TUESDAY, Jan. 2, 2024 – Prolonged fasting before an internal heart exam done under sedation may be unnecessary, new research suggests. Typically, patients undergoing coronary artery catherization...
Being a 'Night Owl' Could Be Tough on Your Arteries
WEDNESDAY, Dec. 27, 2023 – Hardened arteries are almost twice as common in night owls as in early birds, a new study shows. About two in five people (40%) who stay up very late had severely hardened...
Blood Pressure, Cholesterol Before Age 55 Years Impact Risk for Heart Disease
WEDNESDAY, Dec. 20, 2023 – Genetically predicted systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) increase the risk for coronary heart disease (CHD), independent of age,...
No Racial Disparities Seen in Long-Term MACE for Women With CAD
MONDAY, Oct. 30, 2023 – For women with obstructive coronary artery disease (CAD), there are no racial and ethnic disparities in long-term major adverse cardiovascular events (MACE) or cardiovascular...
TCT: Ticagrelor Monotherapy Within One Month of DAPT Noninferior to Continued DAPT
FRIDAY, Oct. 27, 2023 – For patients with acute coronary syndrome (ACS), stopping dual antiplatelet therapy (DAPT) within one month for ticagrelor monotherapy is noninferior and superior to 12...
CHD Risk Increased for Men Exposed to Work Strain, Effort-Reward Imbalance
FRIDAY, Sept. 22, 2023 – Men exposed to job strain or effort-reward imbalance (ERI) have an increased risk for coronary heart disease (CHD), according to a study published online Sept. 19 in...
High-Intensity Statins Underused With Atherosclerotic Cardiovascular Disease
TUESDAY, Sept. 19, 2023 – Among patients with atherosclerotic cardiovascular disease (ASCVD), high-intensity statins are underutilized in routine care, according to a study published online Aug. 2...
Job Frustrations Can Really Be a Heartbreaker for Men
TUESDAY, Sept. 19, 2023 – A job that's demanding but less than rewarding may take a big toll on a man's heart health, a large new study suggests. The study, of nearly 6,500 white-collar workers,...
Opening All Arteries Best When Heart Attack Strikes in Old Age: Study
MONDAY, Aug. 28, 2023 – After a heart attack, elderly adults have better odds for improved health and survival if all major heart vessels are cleared, not just the one that caused the heart attack....
Aspirin Underused in Secondary Prevention of Cardiovascular Disease
THURSDAY, Aug. 24, 2023 – Aspirin is underused in secondary prevention of cardiovascular disease (CVD), according to a study published online Aug. 22 in the Journal of the American Medical...
Heterogeneity Found in Appropriate Use Criteria for Imaging of CAD
WEDNESDAY, Aug. 23, 2023 – U.S. Centers for Medicare & Medicaid Services (CMS)-qualified Appropriate Use Criteria (AUC) for imaging of coronary artery disease (CAD) are heterogeneous and discrepant,...
Cardiac Rehab Lowers Risk for Death After Coronary Artery Bypass Grafting
WEDNESDAY, Aug. 2, 2023 – Cardiac rehabilitation (CR) is associated with lower two-year mortality following coronary artery bypass grafting (CABG), according to a study published online June 29 in...
Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease
June 1, 2020 – AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most ...
FDA Medwatch Alert: Brilinta (ticagrelor) 90 mg tablets, 8-count Physician Sample Bottles: Recall of Lot # JB5047 - Due to Report of Another Medicine in One Bottle
ISSUE: AstraZeneca is notifying physicians and consumers that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of Brilinta (ticagrelor) 90mg...
FDA Approves Expanded Indication for Brilinta to Include Long-Term Use in Patients with a History of Heart Attack
Thursday, 3 September 2015 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a new 60mg dose to be used in patients with a...
Ask a question
To post your own question to this support group, sign in or create an account.